A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
Amgen has created a number of websites to better serve you with specific questions.
Amgen discovers, develops, produces and supplies innovative medicines for patients suffering from serious illnesses. We support health care professionals and patients in the administration and optimization of our innovative therapies.
Below you can see the medicines available in the Saudi Arabia:
Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.
Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.
Mimpara is used in children aged 3 years to less than 18 years of age: to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.
Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.
Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.
Treatment with Prolia makes bone stronger and less likely to break.
Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.
Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.